Inventiva Announces the Implementation of a New ATM Program

Core Viewpoint - Inventiva has filed a shelf registration statement with the SEC for a new At-The-Market (ATM) program, allowing the company to issue and sell up to $100 million in American Depositary Shares (ADS) to finance research and development, working capital, and general corporate purposes [1][2]. Group 1: Registration Statement and ATM Program - The registration statement includes a base prospectus and a sales agreement prospectus, enabling the company to sell ADSs at market prices, with a maximum dilution limit of 30% over a rolling 12-month period [1][3]. - The maximum number of underlying ordinary shares to be admitted to trading on Euronext Paris will represent less than 30% of the already admitted shares over a 12-month period [3][10]. - The sales agent, Piper Sandler, will facilitate the sale of ADSs, with prices varying based on market conditions, and the sales price will not be less than the volume-weighted average price of the company's shares [5][6]. Group 2: Use of Proceeds - The net proceeds from the sale of ADSs will be used for the research and development of lanifibranor, working capital needs, and general corporate purposes [2]. Group 3: Investor Eligibility and Trading - Purchases of ADSs under the ATM program are limited to specific categories of investors, including those regularly investing in the pharmaceutical and biotechnology sectors [4]. - The new ordinary shares will be traded on Euronext Paris, while the issued ADSs will be available on Nasdaq [8]. Group 4: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [12].